Picton Mahoney Asset Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Picton Mahoney Asset Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-70,000	Closed	-$700K	–	888
2022 Q1	$700K	Hold	70,000	–	–	0.02%	602
2021 Q4	$693K	Hold	70,000	–	–	0.02%	631
2021 Q3	$692K	Hold	70,000	–	–	0.03%	573
2021 Q2	$725K	Buy	+70,000	New	+$711K	0.02%	588

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Picton Mahoney Asset Management's MLTX Position: Q2 2022 in Review

Picton Mahoney Asset Management sold out of MoonLake Immunotherapeutics (MLTX) in Q2 2022, closing a stake of 70,000 shares — an estimated $700K sold.

Picton Mahoney Asset Management first reported a position in MLTX in Q2 2021 and held it in 4 quarters. The position peaked at $725K in Q2 2021. 23 funds tracked by Wall St. Rank hold MLTX as of Q2 2022.

Picton Mahoney Asset Management reported no remaining MoonLake Immunotherapeutics position as of Q2 2022 after selling out during the quarter.
Picton Mahoney Asset Management sold 70,000 MoonLake Immunotherapeutics shares in Q2 2022, an estimated $700K.
Picton Mahoney Asset Management first reported a position in MoonLake Immunotherapeutics in Q2 2021 and held it in 4 quarters.
Picton Mahoney Asset Management's MoonLake Immunotherapeutics position peaked at $725K in Q2 2021.
23 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2022.

Based on Picton Mahoney Asset Management's 13F filing for Q2 2022, filed 8 Aug 2022.